Johnson & Johnson booster to be FDA reviewed soon, but recent data complicates it

With the meeting coming up for the FDA to recommend the use of booster vaccines for Johnson & Johnson and Moderna, the new data released causes more confliction.

The FDA has cited that there is not enough evidence to fully recommend the use of a J&J booster vaccine, and now data shows J&J recipients might actually be better off with a mRNA booster from the other two brands.

After the FDA reviews data this week, they will reconvene next week to discuss their final decision. Once that’s made, the CDC will decide who will be eligible for the boosters if approved.

Moderna is seeking approval for the same timeline as Pfizer with 6 month boosters, while J&J has asked for 2-6 months.

The FDA still deems J&J as a protective measure against COVID, but the other brands offer stronger evidence of better protection.

J&J filed data with the FDA stating their vaccine was 80% effective against preventing hospitalizations.

Over the course of the pandemic, over 170 million vaccinated people received the Moderna or Pfizer vaccines, and only 15 million got the J&J.

J&J faced various issues throughout their rollout, from manufacturing issues, to extremely rare side effects of blood clots and neurological reactions.

The one-time shot appealed to most who got it.

Get the latest headlines delivered to your inbox each morning. Sign up for our Morning Edition to start your day. FL1 on the Go! Download the free App for Android (All Android Devices) or iOS (iPhone, iPad).